Showing results (381-390 of 420) with videos related to

Sort By:
Pageof 42
Scientific Reports|August 23, 2022
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical TrialTito R Mendoza, David S Hong, Christine B Peterson, et al.
BMJ Oncology|January 31, 2025
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancerChad Tang, Genevieve P Hartley, Coline Couillault, et al.
Thyroid : Official Journal of the American Thyroid Association|November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW StudyVivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
JCO Precision Oncology|April 22, 2026
Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyEvan Pisick, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Cancer Discovery|April 17, 2018
Precision Targeted Therapy with BLU-667 for RET-Driven CancersVivek Subbiah, Justin F Gainor, Rami Rahal, et al.
The Lancet. Diabetes & Endocrinology|June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 studyVivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid TumorsVivek Subbiah, William Erwin, Osama Mawlawi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin LymphomaFilip Janku, Haeseong Park, S Greg Call, et al.
Cancer|November 2, 2018
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignanciesMinny Bhatty, Shumei Kato, Sarina A Piha-Paul, et al.
Future Oncology (London, England)|November 2, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW studyFrank Griesinger, Giuseppe Curigliano, Vivek Subbiah, et al.
Pageof 42